It also involves the process of producing these compounds, the pharmaceutical ingredients containing them and their use alone in VHb therapy or in combination with other VHb inhibitors. Claim 1: a formula compound (1), including all its stereoisomers or possible ceramic forms, wherein: B is selected from the c83321316c tar group containing one or more fluorine atoms； Z is selected from the H or halogen group； Or B and Z plus the carbide they attach to form a ring of four or seven membersa. The diamond rings of 4-7 optional members are replaced by one or more substitutes selected from asphalt group c833123；oxo, OH and halogen； R¹ is selected from the group comprising heteroaryl and phenyl, optionally substituted with one or more substituents selected from the group comprising halogen and C₁₋₃ alkyl；RZ is selected from the group consisting of - r8310-r8311；C: n, cyclotropile and CF 8323；R³ is selected from the group comprising C₁₋₃carbonyl and CºN alkoxy； R⁴ and R⁵ are independently selected from the group comprising H, methyl and halogen； R⁶ is C₁₋₃ alkyl or C₂₋₃ alkenyl,both optionally substituted with one or more fluorine； R⁷ is selected from the group comprising hydrogen, a C₃₋₇ heterocycloalkyl,e. Cyclopilo, alcoxi c8321c833123 and cf8323；Or salt or solution acceptable to the drugTambién se refiere a procesos para preparar dichos compuestos, composiciones farmacéuticas que los contienen y su uso, solos o en combinación con otros inhibidores de VHB, en la terapia de VHB. Reivindicación 1: Un compuesto de fórmula (1) incluidos todos sus estereoisómeros o formas tautoméricas posibles, en donde: B se selecciona del grupo que comprende alquilo C₁₋₃ opcionalmente sustituido con uno o varios átomos de flúor； Z se selecciona de H o halógeno； o B y Z junto con los carbonos a los que están unidos forman un anillo de 4 - 7 miembros, que opcionalmente contiene uno o varios heteroátomos, en donde el anillo de 4 - 7 miembros opcionalmente está sustituido con uno o varios susti
